Sera Prognostics: Funding, Investors & Team (Oct 2026)
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.
Sera Prognostics has raised $60.4M across 2 funding rounds on record, the most recent an undisclosed round of $10.4M announced in Jun 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Sera Prognostics Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Sera Prognostics Funding Rounds
Sera Prognostics raised $50.0M in an undisclosed round announced in Feb 2025.
1.3 years later, an undisclosed round of $10.4M was announced in Jun 2026.
Sera Prognostics Founders and Leadership Team
No contact details are on record for this team yet.
Sera Prognostics Funding Compared to Other Biotechnology Startups
Sera Prognostics' latest round of $10.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Sera Prognostics in Biotechnology and Salt Lake City
Companies Similar to Sera Prognostics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Sera Prognostics Funding FAQs
What does Sera Prognostics do?
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.
How much funding has Sera Prognostics raised?
Sera Prognostics has raised $60.4M across 2 rounds on record. The most recent is an undisclosed round of $10.4M announced in Jun 2026.
When did Sera Prognostics last raise funding?
Sera Prognostics' most recent funding round on record is an undisclosed round of $10.4M, announced in Jun 2026.
Who founded Sera Prognostics?
FundedIQ lists Gregory Critchfield (Founder), Steven Graves (Founder) at Sera Prognostics.
Where is Sera Prognostics headquartered?
Sera Prognostics is based in Salt Lake City, Utah, United States.
How many employees does Sera Prognostics have?
Sera Prognostics is in the 51-100 employee band.
How does Sera Prognostics' funding compare to other Biotechnology startups?
Sera Prognostics' latest round of $10.4M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Sera Prognostics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Sera Prognostics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.